Four cycles of BEP vs four cycles of VIP in patients with intermediate-prognosis metastatic testicular non seminoma: a randomized study of the EORTC Genitourinary Tract Cancer Cooperative Group
| Autor: | L. de Prijck, J.P. Neijt, Richard Sylvester, Dt Sleijfer, W.W. ten Bokkel Huinink, Laurence Collette, Gerrit Stoter, R. de Wit |
|---|---|
| Přispěvatelé: | Medical Oncology |
| Jazyk: | angličtina |
| Rok vydání: | 1998 |
| Předmět: |
Cancer Research
medicine.medical_specialty medicine.medical_treatment Urology VIP Regimen Bleomycin chemistry.chemical_compound SDG 3 - Good Health and Well-being medicine non-seminatous germ cell cancer Etoposide Testicular cancer SALVAGE THERAPY Chemotherapy Ifosfamide business.industry Induction chemotherapy GERM-CELL TUMORS CHEMOTHERAPY medicine.disease Nitrogen mustard Surgery testicular cancer MODEL Oncology chemistry business medicine.drug |
| Zdroj: | British Jounal of Cancer, 78(6), 828-832. Nature Publishing Group British Journal of Cancer, 76(6), 828-832. Nature Publishing Group |
| ISSN: | 0007-0920 |
| Popis: | We investigated the efficacy and toxicity of induction chemotherapy with cisplatin and etoposide with either bleomycin or ifosfamide in patients with intermediate-prognosis testicular non-seminoma. A total of 84 eligible patients were randomized to receive four cycles of etoposide, ifosfamide, cisplatin (VIP), or four cycles of bleomycin, etoposide, cisplatin (BEP). Intermediate prognosis was defined as any of the following: lymph node metastases 5-10 cm in diameter, lung metastases more than four in number or > 3 cm, HCG 5000-50 000 IU l(-1), AFP > 1000 IU l(-1). The complete response (CR) rates to VIP and BEP were similar, 74% and 79% respectively (P = 0.62). Including the cases in whom viable cancer was completely resected with post-chemotherapy debulking surgery, the percentages of patients who achieved a no-evidence-of-disease status were 80% on VIP and 82% on BEP (P = 0.99). In addition, there were no differences in relapse rate, disease-free and overall survival after a median follow-up of 7.7 years. The 5-year progression-free survival was 85% (95% CI 74-96%) in the VIP arm and 83% (95% CI 71-96%) in the BEP arm, hazard ratio (VIP/BEP) 0.83 (95% CI 0.30-2.28). The VIP regimen was more toxic with regard to bone marrow function; the frequency of leucocytes below 2000 mu l(-1) throughout four cycles was 89% on VIP and 37% on BEP (P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|